PRGO - Perrigo Company plc
| Previous Close | 87.53 |
| Open | 87.98 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 87.23 - 87.98 |
| 52 Week Range | 63.68 - 91.95 |
| Volume | 918,877 |
| Avg. Volume | 1,551,587 |
| Market Cap | 12.47B |
| Beta | 0.72 |
| PE Ratio (TTM) | -4.25 |
| EPS (TTM) | -20.57 |
| Earnings Date | Nov 8, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | 0.64 (0.73%) |
| Ex-Dividend Date | 2017-08-23 |
| 1y Target Est | 83.00 |
- Zacks•4 days ago
4 Medical Product Stocks Likely to Top Q3 Earnings Estimates
The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.
- Investor's Business Daily•12 days ago
Perrigo Sees IBD RS Rating Improve To 73
Perrigo shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Markit•14 days agoSee what the IHS Markit Score report has to say about Perrigo Company PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding PRGO totaled $4.24 billion.
- Barrons.com•23 days ago
Evening Sector Snapshot: Pharmaceuticals Gain, Aluminum Slips
Here are the sectors that made the biggest moves today: Perrigo’s (PRGO) gain led pharmaceuticals higher. Recreational products gained, including Mattel (MAT). DaVita (DVA) boosted medical and nursing ...
- PR Newswire•26 days ago
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent Of Nexium® 24HR Capsules
TASE: PRGO) today announced it has initiated shipments to retail customers of the first-to-market over-the-counter ("OTC") store brand equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. This product is packaged and marketed as store brands or retailer 'own label' brands and provides consumers a high-quality, value alternative to Nexium® 24HR capsules.
- Investor's Business Daily•last month
Generic Drug Makers Face Pricing Issues That Other Pharmas Don't
Everyone knows high prescription drug prices are a problem, but except for pharma stockholders, few people may realize that price cuts are rippling through the generic side of the industry.
- PR Newswire•last month
Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Exalgo® 32mg Extended Release Tablets
TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Exalgo® 32mg extended release tablets (hydromorphone HCl). The company anticipates launching this product by the end of September 2017. Exalgo® 32mg extended release tablets (hydromorphone HCl) is an opioid agonist indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Markit•last monthSee what the IHS Markit Score report has to say about Perrigo Company PLC.
Perrigo Company PLC NYSE:PRGO
Markit•last monthSee what the IHS Markit Score report has to say about Perrigo Company PLC.
Perrigo Company PLC NYSE:PRGO
- MarketWatch•last month
Perrigo says the FDA has given tentative approval to generic acne gel
Perrigo Co. said early Monday that the Food and Drug Administration has granted tentative approval for its generic version of the acne gel Acanya. Perrigo shares rose 1.2% in premarket trade after the ...
- PR Newswire•last month
Perrigo Announces Tentative FDA Approval For The Generic Version Of Acanya® Gel
TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) topical gel 1.2%/2.5%. Acanya® (clindamycin phosphate and benzoyl peroxide) topical gel 1.2%/2.5% is indicated for the topical treatment of acne vulgaris in patients 12 years or older. Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "The R&D team continues its efforts to achieve regulatory approvals for important new products.
- Capital Cube•last month
ETFs with exposure to Perrigo Co. Plc : September 13, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Perrigo Co. Plc Here are 5 ETFs with the largest exposure to PRGO-US. Comparing the performance and risk of Perrigo Co. Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Zacks•last month
Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick
Perrigo's (PRGO) shares rise with Jeff Smith, CEO of Starboard Value, certifying the company as a top investment pick, courtesy its highly potential generic business.
- Investor's Business Daily•last month
Perrigo Scores Relative Strength Rating Upgrade; Hits Key Threshold
Perrigo sees its Relative Strength Rating reach the 80-plus level.
- TheStreet.com•last month
Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business
Smith says Perrigo and Altaba are important investments.
- MarketWatch•last month
Perrigo surges as Starboard Value's Jeff Smith talks up the stock
Shares of Perrigo Co. surged Tuesday after Jeff Smith, chief executive officer of Starboard Value, singled out the pharmaceutical company as a good investment. Perrigo has more potential to boost sales ...
- Reuters•last month
Starboard Value says Amazon sales a boon for Perrigo
The distribution channel of Amazon.com Inc. represents a big opportunity for drug maker Perrigo, Starboard Value founder and CEO Jeffrey Smith said on Tuesday. Smith, speaking at the Delivering Alpha event ...
- CNBC•last month
Starboard Value CEO Smith pushes Perrigo, Altaba as best ideas
Starboard Value Jeffrey Smith pitched store-brand pharmaceutical company Perrigo as his best investment idea now, during a conference Tuesday.
- InvestorPlace•last month
Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy
There’s no doubt that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has made some progress so far this year. Bankruptcy risk seemed material for Valeant stock as recently as earlier this year. Under CEO Joe Papa, however, VRX stock has at least has bought itself some time.
Yahoo Finance Video•9 days agoTrump to scrap a crucial part of Obamacare
The White House is eliminating a crucial part of the Affordable Care Act. President Donald Trump wants to immediately stop payments to insurers. The administration said the government cannot legally continue to make payments. Yahoo Finance’s Alexis Christoforous and Rick Newman figure out how this will impact the insurance industry and patients.
Yahoo Finance Video•10 days agoPres Trump believes he has the cure for Obamacare
President Trump's healthcare bill may have died in Congress, but that's not stopping him from making changes to Obamacare. Later today, the president is expected to sign an executive order that would let Americans buy insurance across state lines. Yahoo Finance’s Alexis Christoforous and Editor-in-Chief Andy Serwer figure out if the the president’s move will help lower premiums.
- CNBC Videos•last month
Jeffery Smith's best idea
Activist investor and CEO of Starboard Value Jeff Smith speaks at Delivering Alpha 2017 about one stock he thinks will benefit from Amazon’s expansion into consumer products.
- CNBC Videos•last month
Starboard Value CEO Jeff Smith: Perrigo and Altaba are ou...
CNBC's Dominic Chu reports on the best stock picks as laid out by Starboard's Jeff Smith at the Delivering Alpha Conference.
- CNBC Videos•last month
Starboard Value CEO Smith: Our best investment idea is Pe...
Starboard Value CEO Jeffrey Smith speaks at Delivering Alpha on his best investment idea, Perrigo.
